A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Journal of the American College of Cardiology

Volumn 50, Issue 14, 2007, Pages 1373-1380

  Schömig, Albert ^a   Dibra, Alban ^a   Windecker, Stephan ^b   Mehilli, Julinda ^a   Suárez de Lezo, José ^c   Kaiser, Christoph ^d   Park, Seung Jung ^e   Goy, Jean Jacque ^h   Lee, Jae Hwan ^f   Di Lorenzo, Emilio ^g   Wu, Jinjin ^a   Jüni, Peter ^b   Pfisterer, Matthias E ^d   Meier, Bernhard ^b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITY OF BASEL   (Switzerland)

^e University of Ulsan College of Medicine   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g S G MOSCATI HOSPITAL   (Italy)

^h Clinique Cecil   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; GENETIC HETEROGENEITY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME;

AGED; BLOOD VESSEL PROSTHESIS; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SIROLIMUS; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBULIN MODULATORS; WORLD HEALTH;

EID: 34548523048     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.06.047     Document Type: Article

References (44)

1. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
2. Eisenberg M.J., and Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 98 (2006) 375-382
3. Ray G.M., Nawarskas J.J., and Frishman W.H. The paclitaxel-eluting stent in percutaneous coronary intervention: part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions. Cardiol Rev 14 (2006) 143-150
4. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
5. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
6. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
7. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
8. Camenzind E. Safety of Drug-Eluting Stents: Insights From Meta Analysis. Available at: http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesand ctus/707009_Camenzind.htm. Accessed February 16, 2007.
9. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
10. Shuchman M. Trading restenosis for thrombosis?. New questions about drug-eluting stents. N Engl J Med 355 (2006) 1949-1952
11. Wijns W.C., and Krucoff M.W. Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?. Eur Heart J 27 (2006) 2737-2739
12. Camenzind E. Treatment of in-stent restenosis-back to the future?. N Engl J Med 355 (2006) 2149-2151
13. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
14. Stone G.W. Perspectives on drug-eluting stent safety and efficacy with regulatory recommendations (2006) Paper presented at: FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee; December 7-8; Washington, DC.
15. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
16. Egger M., Ebrahim S., and Smith G.D. Where now for meta-analysis?. Int J Epidemiol 31 (2002) 1-5
17. Simmonds M.C., Higgins J.P., Stewart L.A., Tierney J.F., Clarke M.J., and Thompson S.G. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2 (2005) 209-217
18. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
19. Cervinka P., Costa M.A., Angiolillo D.J., et al. Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study. Catheter Cardiovasc Interv 67 (2006) 846-851
20. de Lezo J., Medina A., Pan M., et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. (abstr). J Am Coll Cardiol 45 (2005) 75A
21. Di Lorenzo E., Varricchio A., Lanzillo T., et al. Paclitaxel and sirolimus stent implantation in patients with acute myocardial infarction. (abstr). Circulation 112 (2005) U538
22. Han Y.L., Wang X.Z., Jing Q.M., Wang S.L., Ma Y.Y., and Luan B. Comparison of rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease. (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 34 (2006) 123-126
23. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
24. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
25. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
26. Kim Y.H., Park S.W., Lee S.W., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 (2006) 2148-2153
27. Petronio A.S., De Carlo M., Branchitta G., et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 49 (2007) 539-546
28. Lee J.H., Kim H.S., Lee S.W., et al. Prospective randomized trial of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction (2006) Paper presented at: American College of Cardiology 55th Annual Scientific Session; March 11-14; Atlanta, GA.
29. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
30. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
31. Galloe A.M. SORT OUT II-A prospective, multicenter, large-scale, randomized trial of paclitaxel- and sirolimus-eluting stents in "real-world" lesions: nine-month clinical results (2006) Paper presented at: Transcatheter Cardiovascular Therapeutics; October 22-27; Washington, DC.
32. Goy J.J., Stauffer J.C., Siegenthaler M., Benoit A., and Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. J Am Coll Cardiol 45 (2005) 308-311
33. Zhang Q., Zhang R.Y., Zhang J.S., et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 119 (2006) 165-168
34. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140 (1994) 290-296
35. Juni P., Altman D.G., and Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323 (2001) 42-46
36. Juni P., Witschi A., Bloch R., and Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (1999) 1054-1060
37. Sterne J.A.C., Bradburn M.J., and Egger M. Meta-analysis in Stata. In: Egger M., Smith G.D., and Altman D. (Eds). Systematic Reviews in Health Care (2001), Blackwell BMJ Books, London 357
38. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
39. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
40. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
41. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
42. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
43. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
44. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739